Global Primary Biliary Cholangitis Treatment Market Growth (Status and Outlook) 2023-2029

Global Primary Biliary Cholangitis Treatment Market Growth (Status and Outlook) 2023-2029

Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver. It results from a slow, progressive destruction of the small bile ducts of the liver, causing bile and other toxins to build up in the liver, a condition called cholestasis. There's no cure for primary biliary cholangitis, but medications are available to help slow the progression of the disease and prevent complications. Options include: Ursodeoxycholic acid (UDCA) and Obeticholic acid (Ocaliva).

LPI (LP Information)' newest research report, the “Primary Biliary Cholangitis Treatment Industry Forecast” looks at past sales and reviews total world Primary Biliary Cholangitis Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Primary Biliary Cholangitis Treatment sales for 2023 through 2029. With Primary Biliary Cholangitis Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Primary Biliary Cholangitis Treatment industry.

This Insight Report provides a comprehensive analysis of the global Primary Biliary Cholangitis Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Primary Biliary Cholangitis Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Primary Biliary Cholangitis Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Primary Biliary Cholangitis Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Primary Biliary Cholangitis Treatment.

The global Primary Biliary Cholangitis Treatment market size is projected to grow from US$ 639.9 million in 2022 to US$ 2482.6 million in 2029; it is expected to grow at a CAGR of 21.4% from 2023 to 2029.

United States market for Primary Biliary Cholangitis Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Primary Biliary Cholangitis Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Primary Biliary Cholangitis Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Primary Biliary Cholangitis Treatment players cover Novartis, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Teva Pharmaceutical, Retrophin, Lumena Pharmaceuticals and Intercept Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Primary Biliary Cholangitis Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Ursodeoxycholic Acid (UDCA)
Obeticholic Acid (Ocaliva)

Segmentation by application
Hospitals
Clinics
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Bristol-Myers Squibb
Pfizer
GlaxoSmithKline
Teva Pharmaceutical
Retrophin
Lumena Pharmaceuticals
Intercept Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.